Boron Neutron Capture Therapy (BNCT)
Note: This page is educational. BNCT is a specialized radiation modality requiring regulated boron drugs, neutron sources, treatment planning, and radiation-safety infrastructure.
TL;DR
Boron neutron capture therapy (BNCT) is a two-component radiation strategy: deliver boron-10 preferentially to tumor cells, then irradiate with neutrons. When boron-10 captures a neutron, it releases high-linear-energy-transfer particles with very short path lengths. The idea is cellular-scale dose deposition inside boron-loaded tissue. BNCT is no longer purely theoretical: Japan approved borofalan-10B and accelerator-based BNCT products in 2020 for unresectable locally advanced or locally recurrent head and neck cancer, with post-marketing real-world data now published. Outside Japan, it remains a developing clinical and infrastructure frontier. Sources: [1], [2], [3]
1. The core physics
BNCT depends on three linked pieces:
| Component | Role |
|---|---|
| Boron carrier | Delivers boron-10 into tumor tissue |
| Neutron beam | Triggers the capture reaction |
| Treatment planning | Estimates compound biological dose to tumor and normal tissues |
The reaction produces alpha particles and lithium nuclei. Their range is roughly cell-scale, so selective boron uptake matters as much as beam delivery.
2. Why head and neck cancer is a key use case
Recurrent head and neck cancer is difficult because many patients have already received high-dose radiotherapy. Additional irradiation can be limited by mucosa, salivary glands, mandible, carotid artery, spinal cord, skin, and swallowing structures.
BNCT is attractive here because it aims to concentrate lethal dose where boron accumulates while reducing dose to nearby normal tissue. That selectivity is real only if drug uptake, anatomy, beam geometry, and dose planning line up.
3. Clinical maturity
| Setting | Status |
|---|---|
| Japan, recurrent/locally advanced head and neck cancer | Approved and reimbursed under national health insurance since 2020 |
| Post-marketing Japanese data | Published real-world safety and efficacy reports |
| Brain tumors, melanoma, meningioma, other cancers | Investigational or limited clinical experience |
| Broad global oncology practice | Not routine; infrastructure-limited |
4. What changed recently
Historically, BNCT needed nuclear reactors, which made clinical adoption difficult. Accelerator-based neutron sources are changing the logistics. They do not make BNCT easy, but they move it closer to hospital-compatible infrastructure.
The Japan experience matters because it combines:
- a boron drug
- a commercial accelerator-based neutron device
- regulatory approval
- national reimbursement
- post-marketing surveillance
That is a different maturity level from isolated academic feasibility reports.
5. Failure modes
BNCT can fail when:
- boron uptake is heterogeneous
- tumor-to-normal tissue ratio is too low
- the lesion is too large or poorly positioned for the beam
- dose modeling is inaccurate
- prior radiation damage leaves fragile tissues
- carotid, mucosal, or skin toxicity becomes limiting
- recurrence occurs outside the treated volume
The modality is highly technical. "Cellular-scale radiation" is not useful if the boron distribution is wrong.
6. What technologists can build
- Boron-PET analysis for estimating tumor-to-blood and tumor-to-normal uptake.
- Dose engines that integrate physical dose, biological weighting, and boron pharmacokinetics.
- Patient-selection tools that combine anatomy, prior dose, tumor volume, and uptake.
- Registry infrastructure for real-world BNCT outcomes and toxicity.
- Treatment QA dashboards linking neutron beam parameters, drug infusion timing, imaging, and delivered plan.
7. Brazilian context
BNCT would require radiation-safety regulation, accelerator infrastructure, radiopharmacy coordination, medical physics depth, and multidisciplinary head-and-neck oncology expertise. Near-term value for Brazil is likely in medical physics education, dosimetry research, boron-agent development, and collaboration with international BNCT centers.
See also
References
- Hirose K, Konno A, Hiratsuka J, et al. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): an open-label phase II trial. Radiother Oncol 2021;155:182-187. https://doi.org/10.1016/j.radonc.2020.11.001
- Sato M, Hirose K, Takeno S, et al. Safety of Boron Neutron Capture Therapy with Borofalan(10B) and Its Efficacy on Recurrent Head and Neck Cancer: Real-World Outcomes from Nationwide Post-Marketing Surveillance. Cancers (Basel) 2024;16:869. PMID 38473231. https://doi.org/10.3390/cancers16050869
- Hirose K, Sato M. Clinical Results and Prognostic Factors in Boron Neutron Capture Therapy for Recurrent Squamous Cell Carcinoma of the Head and Neck Under the Japan National Health Insurance System. Int J Radiat Oncol Biol Phys 2024;120:796-804. PMID 38580084. https://doi.org/10.1016/j.ijrobp.2024.03.041
- Malouff TD, Seneviratne DS, Ebner DK, et al. Boron Neutron Capture Therapy: A Review of Clinical Applications. Front Oncol 2021;11:601820. PMID 33718149. https://doi.org/10.3389/fonc.2021.601820